Feb 26 (Reuters) - Eli Lilly's experimental weight-loss pill, orforglipron, caused more side effects and treatment ...

LillyPod, which occupies 30,000 square feet in a room the size of a football field, is capable of crunching massive amounts of data at high speeds and is expected to help the Lilly discover and ...

Eli Lilly announced on " Good Morning America " Monday that its GLP-1 weight-loss drug Zepbound will now be available in a new multi-dose KwikPen, giving patients a simpler way to receive a full month ...

The stock looks unstoppable.

Eli Lilly (NYSE:LLY) reported Phase 3 data showing its oral GLP-1 candidate, orforglipron, produced greater blood sugar and weight reduction in adults with type 2 diabetes than Novo Nordisk’s oral ...

Eli Lilly, the drugmaker behind weight-loss treatments Mounjaro and Zepbound, has rapidly overtaken former market leader Novo ...

Eli Lilly and Co. doesn’t owe royalties to Research Corp. Technologies Inc. for Lilly’s “crown jewel” diabetes treatments, which are made with an ingredient produced using RCT’s licensed technology, a ...

A local contractor is completing the buildout of a new manufacturing line in an existing Lilly building that focuses on ...

A clinical trial for diabetes that pit orforglipron, a diabetes and weight-loss pill developed by Eli Lilly, against oral ...

As reported by the Charlotte Business Journal, the filing is valued at roughly $77 million and is tied to work inside an existing Lilly facility described as a new manufacturing line for injectable ...

Lilly agrees to acquire Orna Therapeutics in an all-cash deal.